Asceniv Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established efficacy of ivig therapies, rising awareness of primary immunodeficiency, hospital adoption of immunoglobulin infusions, clinical success in infection reduction, availability of plasma derived antibodies.

The growth in the forecast period can be attributed to increasing pid diagnosis rates, shift toward home infusion models, improved plasma supply management, expansion of specialty immunology services, rising long term therapy compliance. Major trends in the forecast period include rising use of immunoglobulin replacement therapies, growing diagnosis of primary immunodeficiency disorders, expansion of long term antibody infusion treatments, increasing adoption of home based immunotherapy, improved infection prevention in immunocompromised patients.

The rising prevalence of respiratory diseases is expected to drive the growth of the asceniv market in the coming years. Respiratory diseases include conditions that affect the lungs and airways, ranging from infections such as pneumonia to chronic illnesses like asthma and COPD. The increase in respiratory diseases is fueled by factors including air pollution, smoking, climate change, aging populations, and greater exposure to infectious agents. Asceniv supports the treatment of respiratory diseases by providing antibodies that enhance the immune system, helping individuals with immune deficiencies or viral respiratory infections combat pathogens. For instance, in December 2023, according to the National Institutes of Health, a US-based government agency, COPD cases were projected to rise by 112 million, reaching a total of 592 million by 2050, representing 9.5% of the eligible population. Therefore, the growing prevalence of respiratory diseases is driving the growth of the Asceniv market.

The increasing prevalence of immunodeficiency diseases is expected to further propel the growth of the asceniv market. Immunodeficiency diseases occur when the immune system’s ability to combat infections and diseases is compromised or absent. The rising prevalence is driven by improved diagnostic capabilities and an aging population. ASCENIV benefits patients with immunodeficiency diseases by providing concentrated intravenous immunoglobulin therapy that strengthens immune function, reduces vulnerability to infections, and supports overall immune health, improving quality of life. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, there were 6,008 HIV diagnoses in England in 2023 (including cases previously diagnosed abroad), marking a 51% increase from 3,975 cases in 2022. Therefore, the growing prevalence of immunodeficiency diseases is driving the growth of the Asceniv market.

Leading companies in the asceniv market are focusing on product innovations, such as extended room temperature storage conditions, to improve stability, accessibility, and reduce storage and transportation challenges. Extended room temperature storage allows Asceniv to be kept at ambient temperatures for prolonged periods without compromising safety or efficacy. For instance, in March 2024, ADMA Biologics, a US-based biotechnology company, received FDA approval for extended room temperature storage for its intravenous immunoglobulin products, ASCENIV and BIVIGAM. Both products can now be stored at 25°C for up to four weeks during their 36-month shelf life, enhancing usability, inventory management, and access for healthcare providers, particularly in regions with limited refrigeration. ASCENIV is indicated for treating primary humoral immunodeficiency in adults and adolescents, while BIVIGAM is used for multiple forms of this condition.

Major companies operating in the asceniv market are ADMA Biologics Inc.

North America was the largest region in the asceniv market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asceniv market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the asceniv market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the asceniv market by increasing costs related to plasma sourcing, immunoglobulin purification, and international logistics. These impacts are most visible in hospital and homecare distribution channels. Higher tariffs have contributed to pricing pressure for long term immunoglobulin therapies. At the same time, tariffs are supporting domestic plasma collection expansion. This is improving long term supply security for immunodeficiency treatments.

The asceniv market research report is one of a series of new reports that provides asceniv market statistics, including asceniv industry global market size, regional shares, competitors with a asceniv market share, detailed asceniv market segments, market trends and opportunities, and any further data you may need to thrive in the asceniv industry. This asceniv market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Asceniv is an immunoglobulin (human) injection used to enhance the immune system by supplying antibodies that help protect against infections. It is primarily indicated for individuals with primary humoral immunodeficiency (PI), a condition in which the body cannot produce sufficient antibodies, increasing susceptibility to infections.

The primary indications for Asceniv include primary humoral immunodeficiency and other related conditions. Primary humoral immunodeficiency encompasses a group of rare genetic disorders where the immune system’s ability to generate antibodies is compromised. The therapy is available in liquid and lyophilized formulations and is used across various settings, including hospitals, clinics, and home care.

The asceniv market consists of sales of products including Gamunex-C, Privigen, Gammagard, Flebogamma, and Octagam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.